NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Immunic, Inc. (IMUX) Stock Analysis

Immunic, Inc. (IMUX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IMUX

$13.11

+$0.35 (+2.74%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMUX with… →

IMUX Key Statistics

As of Sep 4, 2026
Trading
Open
$12.77
Previous Close
$12.76
Day's Range
12.44–13.17
52-Week Range
5.06–17.43
Volume
420.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.41
Valuation
Market Cap
$178.88M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.64
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$97.17M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
13.64M
1-Year Return
+70.26%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
194.05K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMUX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+145.51%
2025−46.60%
2024−33.33%
2023+7.14%
2022−85.37%
2021−37.41%
2020+57.63%
2019+30.38%
2018−96.87%
2017+36.78%
2016 (partial year)−27.50%

As of September 4, 2026.

IMUX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$97.17M—
2024$0.00−$100.51M—
2023$0.00−$93.61M—
2022$0.00−$120.41M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$103.23M−$97.17M—
2024$0.00—−$98.05M−$100.51M—
2023$0.00—−$99.22M−$93.61M—
2022$0.00—−$86.52M−$120.41M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IMUX Valuation vs Biotechnology Median

Median of 656 stocks
MetricIMUXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Immunic, Inc. (IMUX) is capitalised at $178.88M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 100 employees.

The 52-week range on file runs from $5.06 to $17.43. The most recent close on file for IMUX is $13.11, dated September 4, 2026. That is +$0.35 (+2.74%) against the previous close. The latest close sits 159.09% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $97.17M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −3.64.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.41. Annualized volatility over the trailing 10 years is 117.76%. Over the trailing twelve months the price has returned +70.26%. Measured over 10 years, that is −40.75% a year compounded.

Growth & Income

No dividend is on file for IMUX.

2026 is still running; the price is +145.51% year to date. The strongest complete calendar year on file is 2020 at +57.63%; the weakest is 2018 at −96.87%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Immunic, Inc. (IMUX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immunic, Inc. IMUX $178.88M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Immunic, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Immunic, Inc.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Visit website →